# Peyman Saadat MD, Inc. – FDA Inspection, Feb 20, 2024

Source: https://www.keypedia.com/records/fda_inspections/peyman-saadat-md-inc/e226d855-6e16-4b64-9d28-5ef11a67542a
Source feed: FDA_Inspections

> FDA inspection 1231316 of Peyman Saadat MD, Inc., February 20, 2024. Classification: No Action Indicated (NAI). 2 citations under 21 CFR part 1271. 4 other FDA inspections on record for this company.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1231316
- Company Name: Peyman Saadat MD, Inc.
- Inspection Date: 2024-02-20
- Classification: No Action Indicated (NAI)
- Classification Code: NAI
- Project Area: Blood and Blood Products
- Product Type: Biologics
- Center: Biologics
- Office Name: Center for Biologics Evaluation and Research
- Citation Count: 2

## Related Documents

- [FDA Inspection 1045088 - 2018-03-21](https://www.keypedia.com/records/fda_inspections/peyman-saadat-md-inc/f1ec9f87-5e0b-4d1e-83f0-49baae854f90)
- FDA Inspection 938669 - 2015-07-29
- FDA Inspection 796642 - 2012-08-16
- FDA Inspection 731983 - 2011-06-23

## Related Officers

- [Issuing Officer](https://www.keypedia.com/people/dylan-r-jock/a083cb5e-95d7-491d-9c6d-8c36c5963ddf)

Company: https://www.keypedia.com/companies/peyman-saadat-md-inc/2128187d-8aeb-4e88-ad5f-ae65b674bae7

Office: https://www.keypedia.com/offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d